Gilead Sciences, Inc. with ticker code (GILD) have now 25 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $110.25 and $62.08 with the average share target price sitting at $75.50. (at the time of writing). Given that the stocks previous close was at $66.59 and the analysts are correct then we can expect a percentage increase in value of 13.4%. Also worth taking note is the 50 day moving average now sits at $66.14 and the 200 day moving average is $73.77. The company has a market capitalization of 82.33B. The stock price for the company is currently $66.08 USD
The potential market cap would be $93,341,272,622 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 183.56, revenue per share of $22.00 and a 10.5% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
